Pharmacokinetic evaluation of etravirine

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 12, 2010, Pages 1575-1585

  Dickinson, Laura ^a,b   Khoo, Saye ^b   Back, David ^b  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Efficacy; Etravirine; HIV; Non nucleoside reverse transcriptase inhibitor; Pharmacokinetics

Indexed keywords

ATAZANAVIR; ATORVASTATIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DARUNAVIR; DIGOXIN; EFAVIRENZ; ELVITEGRAVIR; ETHINYLESTRADIOL; ETRAVIRINE; FOSAMPRENAVIR; LOPINAVIR; MARAVIROC; METHADONE; NEVIRAPINE; NORETHISTERONE; OMEPRAZOLE; PAROXETINE; RALTEGRAVIR; RANITIDINE; RIFABUTIN; SILDENAFIL; TENOFOVIR; TIPRANAVIR;

ATYPICAL MYCOBACTERIOSIS; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE PHENOTYPE CORRELATION; GLUCURONIDATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; MYCOBACTERIUM AVIUM; NONHUMAN; REVIEW; SINGLE DRUG DOSE; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 78649311785     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.535811     Document Type: Review

References (66)

1. Joint United Nations Program on HIV/AIDS (UNAIDS) & World Health Organisation (WHO). AIDS Epidemic Update: December 2009, 2009. Available from: http://dataunaidsorg/Pub/Report/2009/JC1700-Epi-Update-2009-enpdf [Last accessed 01 September 2010]
2. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608
3. Gathe J, Bogner J, Santiago S, et al. Comparison of 48 week efficacy and safety of 400 mg QD nevirapine extended release formulation (Viramune XR) versus 200 mg BID nevirapine immediate release formulation (Viramune IR) in combination with Truvada® in antiretroviral (ARV) naive HIV-1 infected patients (VERxVE) [abstract ThLBB202]. XVIII International AIDS Conference, Vienna, Austria; 2010
4. Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47:2550-60 •• A key paper outlining the discovery of diarylpyrimidine drug candidates, including etravirine, from a structural perspective. The paper discusses how the flexibility in binding to reverse transcriptase allows the compounds to escape drug resistance mutations.
5. Kakuda TN, Scholler-Gyure M, Workman C, et al. Single-and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther 2008;13:655-61 • Study comparing the Phase II (800 mg) and Phase III formulations (100, 200 mg) of etravirine. Overall, the 200 mg twice daily dose significantly improved the bioavailability of etravirine and reduced interindividual variability in pharmacokinetics compared to 800 mg twice daily of the Phase II formulation.
6. ClinicalTrials.gov. TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents, 2010. Available from: http://clinicaltrialsgov/ct2/show/NCT00665847 [Last accessed 01 September 2010]
7. Scholler-Gyure M, Kakuda TN, Van Solingen-Ristea RM, et al. Bioavailability of the 100 mg etravirine tablet dispersed in water and of the 25 mg pediatric tablet formulation [abstract MoPe0184]. XVII International AIDS Conference, Mexico City, Mexico, 2008
8. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:4680-6
9. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005;79:12773-82 •• This study identified through sequential passage experiments that development of resistance to etravirine required multiple mutations and in addition to common NNRTI resistance mutations, novel mutations were also observed. Cumulatively, these data suggest etravirine possesses a high genetic barrier to resistance.
10. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010;24:503-14 •• An important study evaluating the resistance profile of etravirine based on 24 week data from the DUET studies. Seventeen etravirine resistance-associated mutations were identified and in order to determine the effect of mutations on virological response weighted genotypic scores and clinical cutoffs were developed.
11. Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 2003;17:2487-94 •• Randomised placebo-controlled monotherapy study (n = 19) in HIV-infected naive patients. Patients receiving etravirine achieved a significantly greater drop in viral load with a quicker daily decay rate in comparison to placebo following 7 days of treatment.
12. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003;17: F49-54 •• A study assessing the short-term efficacy and safety of etravirine over 7 days of therapy in HIV-infected patients with NNRTI resistance. The etravirine-based regimen demonstrated significant antiretroviral activity with a median decrease in viral load of 0.89 log10 and rapid daily decay rate of 0.13 log10 copies/ml/day.
13. Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 2008;9:883-96 •• A pivotal study investigating the safety and efficacy of an etravirine-based regimen in comparison to investigator-selected PI-based therapy in NNRTI-experienced, PI-naive patients. The study was stopped prematurely due to suboptimal performance of the etravirine arm. Etravirine therapy does not appear to be as effective as PI-based regimens in patients with baseline NNRTI and NRTI resistance.
14. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23:2289-300 •• A pivotal combined analysis of the two randomised, placebo-controlled Phase III studies, DUET-1 and DUET-2, evaluating the safety, efficacy and resistance profile of etravirine-based therapy over 48 weeks in patients with triple-class resistance. Significantly more patients achieved viral loads < 50 copies/ml in the etravirine arm. Safety and tolerability of etravirine were comparable to placebo with the exception of rash, which occurred more frequently in the etravirine arm.
15. Montaner J, Yeni P, Clumeck NN, et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis 2008;47:969-78
16. Janssen-Cilag International NV. INTELENCE® 100 mg tablets Summary of Product Characteristics, 2010. Available from: http://wwwmedicinesorguk/emc/ documentaspx?documentId=21185 [Last accessed 01 September 2010]
17. Tibotec Inc. INTELENCE® (etravirine) Tablets US Prescribing Information, 2010. Available from: http://wwwintelence-infocom/intelence/assets/ pdf/INTELENCE-PIpdf [Last accessed 01 September 2010]
18. Scholler-Gyure M, Boffito M, Pozniak AL, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy 2008;28:1215-22
19. Piscitelli S, Baede P, DeDier K, et al. Pharmacokinetics of TMC125 in HIV-infected patients and healthy volunteers [abstract 61]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington, DC, USA; 2002
20. Scholler-Gyure M, Kakuda TN, Raoof A, et al. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009;48:561-74
21. Kakuda TN, Scholler-Gyure M, Peeters M, et al. Pharmacokinetics of etravirine are not affected by sex, age, race, treatment duration or use of enfuvirtide in HIV-1-infected subjects [abstract TuPe0082]. XVII International AIDS Conference, Mexico City, Mexico; 2008 • A population pharmacokinetic analysis of data obtained during the DUET studies. Covariates such as sex, age and race were not significantly associated with etravirine exposure. However, exposure was higher in those co-infected with hepatitis. Increasing adherence and decreasing weight were associated with increasing etravirine AUC0-12 and co-administered tenofovir lowered exposure.
22. Peeters M, Janssen K, Kakuda TN, et al. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharmacother 2008;42:757-65 • This study also compared the pharmacokinetics of once daily vs twice daily etravirine in healthy volunteers and showed that maximum concentrations were 44% higher and trough concentrations 25% lower with similar exposure following once daily dosing. The data supported further investigation in HIV-infected patients.
23. DeJesus E, Lalezari JP, Osiyemi OO, et al. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther 2010;15:711-20
24. Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults. Clin Ther 2010;32:328-37
25. Izurieta P, Kakuda TN, Clark A, et al. Safety and pharmacokinetics of etravirine in pregnant HIV-infected women [abstract PE 41/6]. 12th European AIDS Conference (EACS), Cologne, Germany; 2009 • A small study (n = 5) evaluating etravirine pharmacokinetics in pregnant HIV-infected women during the third trimester of pregnancy. Etravirine pharmacokinetics was comparable to non-pregnant females and no serious malformations were observed. Further study of etravirine in pregnant women is ongoing (TMC114-HIV3015).
26. ClinicalTrials.gov. A study to assess the pharmacokinetics (blood levels) of TMC114 (darunavir) taken with TMC114r (ritonavir), and TMC125 (etravirine) in HIV-1 infected pregnant women, 2010. Available from: http:// clinicaltrialsgov/ct2/show/NCT00855335?term=darunavir&rank=1 [Last accessed 01 September 2010]
27. ClinicalTrials.gov. Study in healthy males to measure darunavir and etravirine in blood, seminal fluid, and rectal tissue (DESeRT), 2010. Available from: http://clinicaltrialsgov/ct2/show/NCT00855088 [Last accessed 01 September 2010]
28. Letendre SL, Ellis RJ, Ances BM, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med 2010;18:45-55
29. Raoof A, Mannens G, Mamidi R, et al. In vivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers [abstract M1342]. 7th AAPS Annual Meeting and Exposition, San Antonio, TX, USA; 2006
30. Schiller DS, Youssef-Bessler M. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin Ther 2009;31:692-704
31. Scholler-Gyure M, Woodfall B, De Marez T, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir [abstract P278]. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2006
32. Scholler M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy subjects [abstract 583]. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, Co, USA; 2006
33. Baede P, Piscitelli S, Graham N, et al. Drug interactions with TMC125, a potent next generation NNRTI [abstract A-1827]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, USA; 2002
34. Scholler-Gyure M, Debroye C, Vyncke V, et al. Effect of TMC125 on sildenafil pharmacokinetics [abstract 45]. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, 2006
35. Scholler-Gyure M, Woodfall B, Bollen S, et al. Pharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving TMC125 with fosamprenavir/ritonavir [abstract A-0370]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, USA; 2006
36. Scholler-Gyure M, Debroye C, Woodfall B, et al. Pharmacokinetic interaction between TMC125 and clarithromycin [abstract 1351]. 44th Annual Meeting of the Infectious Diseases Society of America (IDSA), Toronto, Ontario, Canada; 2006
37. University of Liverpool. HIV Pharmacology Group HIV Drug Interactions Website, 2010. Available from: http://wwwhiv-druginteractionsorg/[Last accessed 01 September 2010]
38. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008;52:4228-32
39. Barrail-Tran A, Yazdanpanah Y, Fagard C, et al. Lack of interaction between etravirine and raltegravir plus darunavir/ritonavir when combined in treatment-experienced patients: a substudy of the ARNS 139 TRIO trial [abstract 606]. 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, USA; 2010
40. Menard A, Solas C, Mokthari S, et al. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases. AIDS 2009;23:869-71
41. Taylor S, Boffito M, Khoo S, et al. Stopping antiretroviral therapy. AIDS 2007;21:1673-82
42. Boffito M, Jackson A, Lamorde M, et al. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. J Acquir Immune Defic Syndr 2009;52:222-7
43. Raoof A, Lachau-Durand S, Verbeeck J, et al. Etravirine has no effect on fet al. development in rats and rabbits [abstract TuPe0013]. XVII International AIDS Conference, Mexico City, Mexico; 2008
44. Gazzard B, Di Perri G, Furrer H, et al. The SENSE trial: Etravirine (ETR) shows fewer neuropsychiatric adverse events than efavirenz in treatment-naive HIV-1 infected patients [abstract LBPe19]. XVIII International AIDS Conference, Vienna, Austria; 2010
45. Imaz A, del Saz SV, Ribas MA, et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2009;52:382-6
46. Nakamura H, Miyazaki N, Hosoya N, et al. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir. J Infect Chemother 2010: published online 30 June 2010, doi: 10.1007/s10156-010- 0082-4
47. Towner W, Lalezari J, Sension MG, et al. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr 2010;53:614-18
48. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009;49:1441-9
49. Briz V, Palladino C, Navarro ML, et al. Efficacy, safety and tolerability of etravirine (ETR) as salvage therapy in HIV-1-infected paediatric patients in clinical practice [abstract CDB0178]. XVIII International AIDS Conference, Vienna, Austria; 2010
50. Thuret I, Chaix ML, Tamalet C, et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS 2009;23:2364-6
51. Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 2009;23:434-5
52. Jaworsky D, Thompson C, Yudin MH, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 2010;15:677-80
53. ClinicalTrials.gov. A clinical trial comparing etravirine to efavirenz in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in treatment-naive HIV-1 infected patients, 2010. Available from: http://clinicaltrialsgov/ct2/show/NCT00903682?term=etravirine&rank=19 [Last accessed 01 September 2010]
54. ClinicalTrials.gov. Evaluating once daily etravirine in treatment-naive adults with HIV infection, 2010. Available from: http://clinicaltrialsgov/ct2/ show/NCT00959894?term=etravirine&rank=1 [Last accessed 01 September 2010]
55. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007;12:789-96
56. Piscitelli SC, Baede P, Van't Klooster G, et al. TMC125 does not alter lopinavir/ritonavir pharmacokinetics in healthy volunteers [abstract A-1824]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, USA; 2002
57. Kakuda TN, Scholler-Gyure M, De Smedt G, et al. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med 2009;10:173-81
58. Davis J, Scholler-Gyure M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects [abstract P43/02]. 11th European AIDS Conference (EACS), Madrid, Spain; 2007
59. Ramanathan S, Kakuda TN, Mack R, et al. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008;13:1011-17
60. Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Pharmacokinetic interaction between the non-nucleoside reverse transcriptase inhibitors (NNRTI) TMC125 and atorvastatin in HIV-negative volunteers [abstract WePeA106]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia; 2007
61. Scholler-Gyure M, van den Brink W, Kakuda TN, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol 2008;48:322-9
62. Scholler-Gyure M, Kakuda TN, Woodfall B, et al. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception 2009;80:44-52
63. Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol 2008;66:508-16
64. Scholler-Gyure M, Woodfall B, Debroye C, et al. Pharmacokinetic interaction between TMC125 and rifabutin [abstract 1059]. 44th Annual Meeting of the Infectious Diseases Society of America (IDSA), Toronto, Ontario, Canada; 2006
65. Scholler-Gyure M, Kakuda TN, Van Solingen-Ristea RM, et al. No clinically relevant effect of etravirine (ETR; TMC125) on digoxin pharmacokinetics in HIV-negative volunteers [abstract P22]. 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, LA, USA; 2008
66. Scholler-Gyure M, Kakuda TN, Bollen S, et al. No pharmacokinetic interaction between TMC125 (etravirine; ETR) and paroxetine in HIV-negative volunteers [abstract P43/01]. 11th European AIDS Conference (EACS), Madrid, Spain; 2007